ADMA Biologics, Inc. ADMA

ADMA$ The more FDA approvals ADMA gets the more attractive the company becomes as a target for a buyout. It’s only a matter of time.

$ADMA https://www.google.com/amp/s/seekingalpha.com/amp/article/4429356-adma-getting-unstuck-between-a-rock-and-a-hard-place

$ADMA https://www.smarteranalyst.com/new-blurbs/h-c-wainwright-thinks-adma-biologics-stock-is-going-to-recover/

$ADMA Achieved First Quarter 2021 Total Revenues of $16.0 Million, a 57% Increase Over First Quarter 2020. Significantly Expanded Total Asset Value to $235.7 Million, Including $94.1 Million in Inventories

$ADMA I predict 17 million Q1 revenue.

$ADMA https://www.nasdaq.com/articles/why-adma-biologics-adma-might-surprise-this-earnings-season-2021-05-10

$ADMA Q1 will be a blowout and the shorts will get blown out. They’ll have no choice but to cover their positions.

Is there any chance to see good numbers tomorrow?

$ADMA https://www.google.com/amp/s/seekingalpha.com/amp/article/4418095-adma-biologics-sell-off-provides-buying-opportunity-ahead-of-projected-growth

ADMA$ Big volume today but little price action. Something is brewing.